ReviewExpert review of pharmacoeconomics & outcomes research2015
Estimates of utility weights in hemophilia: implications for cost-utility analysis of clotting factor prophylaxis.
Review in Expert review of pharmacoeconomics & outcomes research, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed, 1 synthesis or guideline pooled it, 15 citations in OpenAlex.
- Can The EQ-5D Detect Meaningful Change? A Systematic Review.PharmacoEconomics · 2015Pooled it
- Economic Burden of Haemophilia from a Societal Perspective: A Scoping Review.PharmacoEconomics - open · 2025Review
- Mapping the Haem-A-QoL to the EQ-5D-5L in patients with hemophilia.Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation · 2022Article
- The effect of emicizumab prophylaxis on long-term, self-reported physical health in persons with haemophilia A without factor VIII inhibitors in the HAVEN 3 and HAVEN 4 studies.Haemophilia : the official journal of the World Federation of Hemophilia · 2021Article
- Evaluating the psychometric properties of the EQ-5D-5L and SF-6D among patients with haemophilia.The European journal of health economics : HEPAC : health economics in prevention and care · 2021Article
- Evidence of a disability paradox in patient-reported outcomes in haemophilia.Haemophilia : the official journal of the World Federation of Hemophilia · 2021Article
- Patient Preferences to Assess Value IN Gene Therapies: Protocol Development for the PAVING Study in Hemophilia.Frontiers in medicine · 2021Article
- Preferences and Health-Related Quality-of-Life Related to Disease and Treatment Features for Patients with Hemophilia A in a Canadian General Population Sample.Patient preference and adherence · 2021Article
- The effects of joint disease, inhibitors and other complications on health-related quality of life among males with severe haemophilia A in the United States.Haemophilia : the official journal of the World Federation of Hemophilia · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
Abstract
Estimates of preference-weighted health outcomes or health state utilities are needed to assess improvements in health in terms of quality-adjusted life-years. Gains in quality-adjusted life-years are used to assess the cost-effectiveness of prophylactic use of clotting factor compared with on-demand treatment among people with hemophilia, a congenital bleeding disorder. Published estimates of health utilities for people with hemophilia vary, contributing to uncertainty in the estimates of cost-effectiveness of prophylaxis. Challenges in estimating utility weights for the purpose of evaluating hemophilia treatment include selection bias in observational data, difficulty in adjusting for predictors of health-related quality of life and lack of preference-based data comparing adults with lifetime or primary prophylaxis versus no prophylaxis living within the same country and healthcare system.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.